Disease · MONDO_0002363

papilloma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. papilloma. Diseases, record MONDO_0002363. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002363

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: papilloma; Open Targets
Open Targets ID: MONDO_0002363; Open Targets
Other names: papilloma (except papilloma of bladder M-81201) (morphologic abnormality), papilloma, benign; Open Targets
Disease Ontology: DOID:2615; Disease Ontology
MeSH: D010212; MeSH
NCI Thesaurus: C7440; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 1 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROPRANOLOL	CHEMBL27	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CIDOFOVIR	CHEMBL5314375	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/154	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PTGS2	Prostaglandin G/H synthase 2	1	Cyclooxygenase-2 inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	1	Vascular endothelial growth factor A inhibitor	Phase 2	https://conductscience.org/library/genes/7422	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00571701	Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis	Phase 2	50	2017-02-23	Recurrent Respiratory Papillomatosis	CELECOXIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02632344	Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients	Phase 2	21	2023-07-03	Recurrent Respiratory Papillomatosis	PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01020747	Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)	Phase 1	20	2012-12-04	Recurrent Respiratory Papillomatosis	BEVACIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02555800	Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis	Phase 2	36		Recurrent Respiratory Papillomatosis	BEVACIZUMAB, CIDOFOVIR	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04645602	Merck IIT: RRP Pembro and Lenvatinib	Phase 2	20		Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease	LENVATINIB, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01058317	Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis	Phase 2/3	0		Recurrent Respiratory Papillomatosis	PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Celecoxib vs Placebo: serious adverse events	3 of 40	2 of 39	79	NCT00571701

Source Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
35397828	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002363

GET https://conductscience.org/api/diseases/v1/MONDO_0002363/drugs

API reference For AI assistants